Sloughing Prostatic Tissue, a Rare Complication Post Rezum Therapy: A Case Report.

Cureus

Urology, Ministry of the National Guard-Health Affairs, Riyadh, SAU.

Published: November 2020

Benign prostatic hyperplasia (BPH) is the most prevalent urological disease in men that leads to lower urinary tract symptoms (LUTS). The clinical presentation is, most likely, obstructive symptoms such as intermittency, hesitancy and poor stream, due to the obstructive nature of the pathology. BPH treatment approach varies. However, they can be divided into two main approaches which are non-surgical and surgical. Non-surgical methods usually started first, such as lifestyle modifications, watchful waiting, and medications. Hence, surgical intervention remains the mainstay of treatment to relieve clinical symptoms. Although transurethral resection of the prostate (TURP) is the gold standard, management is shifting towards minimally invasive surgeries such as Rezūm due to its good outcome and fewer adverse effects. We present a case of prostatic tissue sloughing, a rare complication post Rezūm system therapy in a 50-year-old male.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772175PMC
http://dx.doi.org/10.7759/cureus.11722DOI Listing

Publication Analysis

Top Keywords

prostatic tissue
8
rare complication
8
complication post
8
sloughing prostatic
4
tissue rare
4
post rezum
4
rezum therapy
4
therapy case
4
case report
4
report benign
4

Similar Publications

Background: FOXF2 was reported to involve in a variety of biological behaviors that include the development of the central nervous system, tissue homeostasis, epithelia-mesenchymal interactions, regulation of embryonic development, and organogenesis.

Purpose: Understanding how FOXF2 influences the growth and development of cancer could provide valuable insights for researchers to develop novel therapeutic strategies.

Results: In this review, we investigate the underlying impact of FOXF2 on tumor cells, including the transformation of cellular phenotype, capacity for migration, invasion, and proliferation, colonization of circulating cells, and formation of metastatic nodules.

View Article and Find Full Text PDF

Multi-Omics Study Reveals Nc886/vtRNA2-1 as a Positive Regulator of Prostate Cancer Cell Immunity.

J Proteome Res

December 2024

Facultad de Ciencias, Universidad de la República, Sección Genómica Funcional, Montevideo 11400, Uruguay.

Noncoding RNA 886 has emerged as a pivotal regulatory RNA with distinct functions across tissues, acting as a regulator of protein activity by directly binding to protein partners. While it is well recognized as a tumor suppressor in prostate cancer, the underlying molecular mechanisms remain elusive. To discover the principal pathways regulated by nc886 in prostate cancer, we used a transcriptomic and proteomic approach analyzing malignant DU145, LNCaP, PC3, and benign RWPE-1 prostate cell line models transiently transfected with in vitro transcribed nc886 or antisense oligonucleotides.

View Article and Find Full Text PDF

Background: Signet-ring cell carcinoma (SRCC) originates from undifferentiated stem cells in the neck of glands within the lamina propria of the mucosa. Primarily affecting the stomach, SRCC can also involve the breast, pancreas, gallbladder, colon, and bladder, although these cases are rare. SRCC of the prostate is extremely rare, and diagnosing it pelvic puncture is particularly challenging.

View Article and Find Full Text PDF

Introduction Prostate-specific antigen density (PSAD), calculated by dividing serum PSA levels by prostate volume, offers greater specificity and accuracy than serum PSA alone in detecting prostate cancer (PCa). This study aimed to evaluate the diagnostic performance of PSAD in PCa detection across different PSA levels and its correlation with Gleason scores. Methods This retrospective, single-center study reviewed data from 154 patients with suspected PCa who underwent prostate MRI between July 2021 and July 2023.

View Article and Find Full Text PDF

Background: Abnormal expression of six-transmembrane epithelial antigen of prostate 4 (STEAP4) has been implicated in the carcinogenesis of hepatocellular carcinoma (HCC). However, the biological role and regulatory mechanisms of STEAP4 in HCC remain unclear.

Methods And Results: Here, we analyzed STEAP4 expression levels and differentially expressed genes (DEGs) between STEAP4 high- and low-expression groups using multiple databases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!